(Reuters Health) -
Men who were exposed to Agent Orange chemicals used during the Vietnam
War are at higher risk for life-threatening prostate cancer than
unexposed veterans, researchers have found.
What's more, those who served where the
herbicide was used were diagnosed with cancer about five years earlier
than other men, on average, in the new study.
"This
is a very, very strong predictor of lethal cancer," said urologist Dr.
Mark Garzotto, who worked on the study at the Portland Veterans Affairs
Medical Center in Oregon.
Read the full Reuters Health report
Wednesday, May 15, 2013
Gene Test for Prostate Cancer Shows Promise
Medscape. May 08, 2013
SAN DIEGO, California — A genetic test can predict the aggressiveness of prostate cancer, a new study shows.
The 17-gene test predicts whether tumors will progress to high-grade or postsurgical stage III disease.
"We think this will allow patients and doctors to make more confident decisions," study coauthor Eric Klein, MD, told Medscape Medical News. "That will be a boon to everyone and it will save the system money."
The results of the study were presented here at the American Urological Association 2013 Annual Scientific Meeting.
Read the full Medscape report
(Free sign-up may be required)
SAN DIEGO, California — A genetic test can predict the aggressiveness of prostate cancer, a new study shows.
The 17-gene test predicts whether tumors will progress to high-grade or postsurgical stage III disease.
"We think this will allow patients and doctors to make more confident decisions," study coauthor Eric Klein, MD, told Medscape Medical News. "That will be a boon to everyone and it will save the system money."
The results of the study were presented here at the American Urological Association 2013 Annual Scientific Meeting.
Read the full Medscape report
(Free sign-up may be required)
New AUA Guideline for Castration-Resistant Prostate Cancer
Medscape. May 09, 2013
The American Urological Association (AUA) has issued a new guideline for the management of castration-resistant prostate cancer (CRPC) that provides a "rational basis" for treatment decisions.
Those decisions are now "complex" because a group of treatment options for metastatic disease has emerged in a short period of time, according to a press release issued at AUA 2013 Annual Scientific Meeting, held in San Diego, California.
Read the full Medscape report
(Free sign-up may be required)
The American Urological Association (AUA) has issued a new guideline for the management of castration-resistant prostate cancer (CRPC) that provides a "rational basis" for treatment decisions.
Those decisions are now "complex" because a group of treatment options for metastatic disease has emerged in a short period of time, according to a press release issued at AUA 2013 Annual Scientific Meeting, held in San Diego, California.
Read the full Medscape report
(Free sign-up may be required)
Testosterone Benefits Hypogonadal Men With Type 2 Diabetes
Medscape. May 08, 2013.
PHOENIX — Testosterone replacement reverses insulin resistance in hypogonadal men with type 2 diabetes, preliminary data suggest. The findings, from a randomized trial in 81 men, were reported by Paresh Dandona, MD, PhD, head of the division of endocrinology, diabetes, and metabolism at the University of Buffalo, State University of New York, at the American Association of Clinical Endocrinologists 2013 Scientific & Clinical Congress last week.
"Hypogonadotropic hypogonadism [HH] in type 2 diabetes is a factor related to insulin resistance and may be contributing to it. Administration of testosterone over a period of 6 months largely reverses that state of insulin resistance," said Dr. Dandona.
Read the full Medscape report
(Free sign-up may be required)
PHOENIX — Testosterone replacement reverses insulin resistance in hypogonadal men with type 2 diabetes, preliminary data suggest. The findings, from a randomized trial in 81 men, were reported by Paresh Dandona, MD, PhD, head of the division of endocrinology, diabetes, and metabolism at the University of Buffalo, State University of New York, at the American Association of Clinical Endocrinologists 2013 Scientific & Clinical Congress last week.
"Hypogonadotropic hypogonadism [HH] in type 2 diabetes is a factor related to insulin resistance and may be contributing to it. Administration of testosterone over a period of 6 months largely reverses that state of insulin resistance," said Dr. Dandona.
Read the full Medscape report
(Free sign-up may be required)
AUA Issues New Guidelines on PSA Screening
Medscape. May 03, 2013
New guidelines on prostate cancer screening, issued today by the American Urological Association (AUA), are supportive of routine use of the prostate-specific antigen (PSA) test in healthy men, but only for a specified age group, and only after discussion between a man and his physician.
Specifically, the new guidelines state that men 55 to 69 years of age who are at average risk and asymptomatic can consider PSA screening. They should speak to the their physician about the benefits and harms of testing to determine the best course of action.
Read the full Medscape report
(free sign-up may be required)
New guidelines on prostate cancer screening, issued today by the American Urological Association (AUA), are supportive of routine use of the prostate-specific antigen (PSA) test in healthy men, but only for a specified age group, and only after discussion between a man and his physician.
Specifically, the new guidelines state that men 55 to 69 years of age who are at average risk and asymptomatic can consider PSA screening. They should speak to the their physician about the benefits and harms of testing to determine the best course of action.
Read the full Medscape report
(free sign-up may be required)
Subscribe to:
Posts (Atom)